CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Atovaquone/AzithromycinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection

This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.

NCT04339426 Covid19 Drug: Atovaquone/Azithromycin
MeSH:Infection

Primary Outcomes

Description: COVID-19 serology testing

Measure: Virology Cure Rate

Time: 10 days

Secondary Outcomes

Description: Measure incidence of diarrhea, vomiting, nausea and constipation

Measure: Incidence of GI adverse events

Time: 47 days

Description: 12-Lead ECG daily if QTc >500 msec

Measure: Cardiac Toxicity

Time: 10 days

Other Outcomes

Description: Measure blood counts

Measure: Changes in WBC w Diff, B cells, T cells, NK cells

Time: 10 days

Description: Measure changes in plasma cytokines throughout course of infection

Measure: Changes in cytokine levels, IL-1, IL-6, IL-12, IL-18, TNF-a

Time: 10 days

No related HPO nodes (Using clinical trials)